The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

11 Oct 2021 15:15

RNS Number : 7011O
Instem plc
11 October 2021
 

Instem plc("Instem" or the "Company")

Director/PDMR Dealings

Instem (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, has been notified that, on 11 October 2021, Nigel Goldsmith, Chief Financial Officer, acquired 2,500 ordinary shares in the Company at a price of 825p per share. Following this acquisition, Mr. Goldsmith is interested in 2,500 ordinary shares, representing 0.01 per cent. of the ordinary shares in issue.

 

For further information, please contact:

Instem plc

via Walbrook

Phil Reason, CEO

Nigel Goldsmith, CFO

 

Singer Capital Markets (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Peter Steel

Rachel Hayes

Alex Bond

 

Walbrook Financial PR

 

+44 (0) 20 7933 8780

Tom Cooper

instem@walbrookpr.com

Nick Rome

 

 

About Instem 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services now address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit www.instem.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Nigel Goldsmith

2

Reason for the notification

a)

Position/status

Chief Financial Officer and PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Instem plc

b)

LEI

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 10 pence each

 

 

GB00B3TQCK30

b)

Nature of the transaction

Purchase of ordinary shares

c)

 

Price(s) and volume(s)

 

Price

Volume

825 pence

2,500

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A - single transaction

e)

Date of the transaction

11/10/2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSBDGSBBDGBB
Date   Source Headline
21st Nov 20237:00 amRNSCancellation - Instem Plc
21st Nov 20237:00 amRNSCancellation of admission to trading
20th Nov 202312:33 pmRNSScheme becomes Effective
20th Nov 20237:30 amRNSSuspension - Instem PLC
17th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
16th Nov 20233:23 pmRNSIssuance of Shares following Court Sanction
16th Nov 20232:30 pmRNSCourt Sanction of the Scheme
16th Nov 202310:02 amRNSForm 8.5 (EPT/RI)
15th Nov 20231:40 pmPRNForm 8.3 - Instem Plc
15th Nov 202310:16 amRNSForm 8.5 (EPT/RI)
14th Nov 20235:30 pmRNSInstem
14th Nov 20233:01 pmGNWForm 8.3 - Instem plc
14th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
14th Nov 202311:08 amRNSForm 8.5 (EPT/RI)
14th Nov 202310:19 amRNSForm 8.3 - Instem Plc
13th Nov 20232:30 pmPRNForm 8.3 - Instem Plc
13th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
13th Nov 202310:03 amRNSForm 8.5 (EPT/RI) - Instem plc
13th Nov 202310:00 amRNSForm 8.3 - Instem Plc
10th Nov 20233:14 pmPRNForm 8.3 - Instem Plc
10th Nov 202312:03 pmGNWForm 8.3 - Instem plc
10th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
10th Nov 202310:24 amRNSForm 8.3 - Instem Plc
9th Nov 20233:27 pmRNSForm 8.3 - Instem PLC
9th Nov 20231:42 pmPRNForm 8.3 - Instem Plc
9th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
9th Nov 202310:17 amRNSForm 8.3 - Instem Plc
8th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
7th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
7th Nov 202311:40 amRNSForm 8.5 (EPT/RI)
7th Nov 20237:00 amRNSSatisfaction of Conditions
6th Nov 20234:28 pmRNSForm 8.3 - INSTEM PLC (replaces RNS 5325S &5364S)
6th Nov 20234:00 pmRNSForm 8.3 - INSTEM PLC (cancel & replace RNS5325)
6th Nov 20233:05 pmRNSForm 8.3 - INSTEM PLC
6th Nov 20233:00 pmRNSForm 8.3 - Instem PLC
6th Nov 20232:10 pmGNWForm 8.3 - Instem Plc
6th Nov 20231:30 pmPRNForm 8.3 - Instem Plc
6th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
3rd Nov 20235:56 pmRNSHolding(s) in Company
3rd Nov 20231:52 pmPRNForm 8.3 - Instem Plc
3rd Nov 20231:39 pmRNSHolding(s) in Company
3rd Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
3rd Nov 20239:49 amRNSForm 8.5 (EPT/RI)
3rd Nov 20237:05 amRNSForm 8.3 - Instem plc
2nd Nov 20232:25 pmRNSResults of Court Meeting and General Meeting
31st Oct 20239:39 amRNSForm 8.5 (EPT/RI)
30th Oct 202310:09 amRNSForm 8.5 (EPT/RI)
30th Oct 20237:00 amRNSOffer Update
27th Oct 20233:00 pmBUSForm 8.3 - INS LN
27th Oct 20231:09 pmGNWForm 8.3 - Instem Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.